Cardiovascular Risk Factors, Age-Related Cognitive Decline
Conditions
Brief summary
Tart cherries are a rich source of antioxidants. Studies have shown that tart cherries exert anti-oxidative and anti-inflammatory properties. The purpose of this study is to learn about the effects of drinking tart cherry juice on cardiovascular and cognitive health.
Detailed description
Thirty-seven older adults were randomly assigned to drink 16 oz per day of either tart cherry juice or placebo drink for 12 weeks. Blood and urine samples were collected at baseline and 12 weeks to assess biomarkers. Physical activity and 3-day diet records were also collected throughout the study.
Interventions
OTHERTart cherry juice
16 fl. oz of tart cherry juice
OTHERPlacebo
16 fl. oz of placebo
Sponsors
University of Delaware
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
65 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
• Age 65-80
Exclusion criteria
* Allergic to tart cherries * Heavy smoker * Taking medications that affect cognitive function * History of neurological disorders * History of traumatic brain injury * History of stroke * Clinical diagnosis of diabetes * Clinical diagnosis of Alzheimer's Disease/Dementia * GI disease * Kidney disease * Liver disease * Cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive function | Baseline and 12 weeks | Change from baseline in cognitive test performance at 12 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiovascular risk factors | Baseline and 12 weeks | Fasting blood samples were collected at baseline and 12 weeks. Change from baseline in cardiovascular risk factors including blood lipid profiles, atherogenic risk ratios, blood glucose, hemoglobin A1c, insulin, and blood pressure at 12 weeks. |
| Oxidative stress markers | Baseline and 12 weeks | Fasting blood samples were collected at baseline and 12 weeks. Change from baseline in plasma 8-oxoguanine (ng/ml), plasma 8-hydroxy-2deoxy-guanosine (ng/mL), plasma hydroxynonenal (ng/ml), and plasma malondialdehyde (pmole/L) at 12 weeks. |
| Inflammatory markers | Baseline and 12 weeks | Fasting blood samples were collected at baseline and 12 weeks. Change from baseline in plasma tumor-necrosis factor-α (pg/mL) and plasma high-sensitivity C-reactive protein (ng/mL) at 12 weeks. |
Countries
United States
Outcome results
None listed